OS Therapies (NYSE:OSTX) Coverage Initiated at Maxim Group

Stock analysts at Maxim Group started coverage on shares of OS Therapies (NYSE:OSTX) in a research note issued to investors on Tuesday,Benzinga reports. The brokerage set a “buy” rating and a $8.00 price target on the stock. Maxim Group’s price target would indicate a potential upside of 288.35% from the company’s current price.

OSTX has been the subject of a number of other research reports. EF Hutton Acquisition Co. I upgraded shares of OS Therapies to a “strong-buy” rating in a report on Tuesday, September 3rd. Brookline Capital Management upgraded shares of OS Therapies to a “strong-buy” rating in a report on Thursday, August 22nd.

OS Therapies Price Performance

OSTX stock opened at $2.06 on Tuesday. OS Therapies has a 12 month low of $1.58 and a 12 month high of $4.90. The business has a 50-day moving average of $2.78.

Institutional Trading of OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC bought a new stake in shares of OS Therapies Inc (NYSE:OSTX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 10,045 shares of the company’s stock, valued at approximately $28,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.